| Title | Mesenchymal stem cells in fibrotic diseases-the two sides of the same coin |
| Author | |
| Corresponding Author | Xiao, Guo-zhi; Cao, Hui-ling |
| Publication Years | 2022-07-01
|
| DOI | |
| Source Title | |
| ISSN | 1671-4083
|
| EISSN | 1745-7254
|
| Abstract | Fibrosis is caused by extensive deposition of extracellular matrix (ECM) components, which play a crucial role in injury repair. Fibrosis attributes to similar to 45% of all deaths worldwide. The molecular pathology of different fibrotic diseases varies, and a number of bioactive factors are involved in the pathogenic process. Mesenchymal stem cells (MSCs) are a type of multipotent stem cells that have promising therapeutic effects in the treatment of different diseases. Current updates of fibrotic pathogenesis reveal that residential MSCs may differentiate into myofibroblasts which lead to the fibrosis development. However, preclinical and clinical trials with autologous or allogeneic MSCs infusion demonstrate that MSCs can relieve the fibrotic diseases by modulating inflammation, regenerating damaged tissues, remodeling the ECMs, and modulating the death of stressed cells after implantation. A variety of animal models were developed to study the mechanisms behind different fibrotic tissues and test the preclinical efficacy of MSC therapy in these diseases. Furthermore, MSCs have been used for treating liver cirrhosis and pulmonary fibrosis patients in several clinical trials, leading to satisfactory clinical efficacy without severe adverse events. This review discusses the two opposite roles of residential MSCs and external MSCs in fibrotic diseases, and summarizes the current perspective of therapeutic mechanism of MSCs in fibrosis, through both laboratory study and clinical trials. |
| Keywords | |
| URL | [Source Record] |
| Indexed By | |
| Language | English
|
| SUSTech Authorship | Corresponding
|
| Funding Project | National Key Research and Development Program of China[2019YFA0906001]
; National Natural Science Foundation of China["82022047","81972100"]
; Guangdong Provincial Science and Technology Innovation Council[2017B030301018]
; project of Huazhong University of Science and Technology Union Shenzhen Hospital["NY2021029","NY2021030","NY2021031"]
|
| WOS Research Area | Chemistry
; Pharmacology & Pharmacy
|
| WOS Subject | Chemistry, Multidisciplinary
; Pharmacology & Pharmacy
|
| WOS Accession No | WOS:000830960900001
|
| Publisher | |
| ESI Research Field | PHARMACOLOGY & TOXICOLOGY
|
| Data Source | Web of Science
|
| Citation statistics |
Cited Times [WOS]:5
|
| Document Type | Journal Article |
| Identifier | http://kc.sustech.edu.cn/handle/2SGJ60CL/365005 |
| Department | Department of Biochemistry 南方科技大学医学院 |
| Affiliation | 1.Huazhong Univ Sci & Technol, Dept Orthoped, Union Shenzhen Hosp, Shenzhen 518000, Peoples R China 2.CASTD Regengeek Shenzhen Med Technol Co Ltd, Shenzhen 518000, Peoples R China 3.Southern Univ Sci & Technol, Dept Biochem, Sch Med,Shenzhen Key Lab Cell Microenvironm, Guangdong Prov Key Lab Cell Microenvironm & Dis R, Shenzhen 518055, Peoples R China |
| Corresponding Author Affilication | Department of Biochemistry; School of Medicine |
| Recommended Citation GB/T 7714 |
Qin, Lei,Liu, Nian,Bao, Chao-le-meng,et al. Mesenchymal stem cells in fibrotic diseases-the two sides of the same coin[J]. ACTA PHARMACOLOGICA SINICA,2022.
|
| APA |
Qin, Lei.,Liu, Nian.,Bao, Chao-le-meng.,Yang, Da-zhi.,Ma, Gui-xing.,...&Cao, Hui-ling.(2022).Mesenchymal stem cells in fibrotic diseases-the two sides of the same coin.ACTA PHARMACOLOGICA SINICA.
|
| MLA |
Qin, Lei,et al."Mesenchymal stem cells in fibrotic diseases-the two sides of the same coin".ACTA PHARMACOLOGICA SINICA (2022).
|
| Files in This Item: | There are no files associated with this item. | |||||
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.
;
Edit Comment